<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04592445</url>
  </required_header>
  <id_info>
    <org_study_id>09868</org_study_id>
    <nct_id>NCT04592445</nct_id>
  </id_info>
  <brief_title>Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF</brief_title>
  <acronym>Rebalance-HF</acronym>
  <official_title>ENDOVASCULAR ABLATION OF THE RIGHT GREATER SPLANCHNIC NERVE IN Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF: Feasibility Study: Randomized Controlled Feasibility Trial- Rebalance HF Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axon Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axon Therapies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical evaluation is to assess the safety and initial effectiveness&#xD;
      of catheter-based unilateral ablation of the right greater splanchnic nerve (GSN) in subjects&#xD;
      having heart failure with preserved ejection fraction (HFpEF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical investigation is a prospective, multi-center randomized, sham control, double&#xD;
      blinded feasibility clinical study. Both the subject and the noninvasive cardiologist that is&#xD;
      caring for the subject will be blinded to the assigned cohort (treatment or sham). The&#xD;
      interventional cardiologist who performs the index procedure will not be blinded.&#xD;
&#xD;
      Subjects who meet the eligibility criteria and are enrolled will be randomized 1:1 to either&#xD;
      ablation of the right GSN using the Axon System (treatment cohort) or sham (control cohort)&#xD;
      at the time of the procedure.&#xD;
&#xD;
      This study will enroll up to 100 subjects at an anticipated 20 US sites. Subject follow up is&#xD;
      at 1, 3, 6, and 12 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects randomized 1:1 (treatment to sham control); no cross over</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Subject and HF Cardiologist providing care are blinded. Interventionalist who performs the Index procedure in not</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Endpoint</measure>
    <time_frame>1 Month</time_frame>
    <description>Change in mean PCWP at 1 month follow up evaluated as a repeated measure at rest, legs up and exercise (20W) as compared to the baseline PCWP evaluation. This reduction will be assessed in all subjects (both treated and control) to explore mechanism of action</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Outcome</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluation of device or procedure-related serious adverse events at 1-month follow up based on Clinical Events Committee (CEC) assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Endpoints</measure>
    <time_frame>1, 3, 6, and 12 months</time_frame>
    <description>* Quality of Life: Change in KCCQ score evaluated over time from baseline and 1, 3, 6, and 12-months follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Endpoints</measure>
    <time_frame>1, 3, 6, and 12 months</time_frame>
    <description>*Change in 6MWT distance evaluated over time from baseline and 1, 3, 6, and 12 months follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Endpoints</measure>
    <time_frame>1, 3, 6, and 12 months</time_frame>
    <description>*Incidence of heart failure hospitalization through 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Endpoints</measure>
    <time_frame>1 month</time_frame>
    <description>*Reduction in PCWP at 1 month follow up at rest, legs up, exercise at 20W and peak exercise as compared to the baseline PCWP evaluation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Axon Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive treatment with the Satera Ablation System following administration of anesthesia access to the R GSN and ablation of the GSN at 1-2 levels will occur.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Control Arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Following administration of anesthesia subjects will have femoral vein access only. Procedure choreography to mimic procedure steps and length.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Satera GSN Ablation</intervention_name>
    <description>The Axon procedure consists of a small needle puncture made in the groin to pass standard sheaths, wires, and access devices into the femoral vein, using standard access methods. The right GSN will be ablated transvenously from the right intercostal veins where it crosses at the 10th and 11th thoracic vertebrae from the intercostal vein intersection with the azygos vein. Placement of the access devices and Axon catheter is confirmed using standard fluoroscopic imaging. Once positioning is confirmed, GSN ablation can commence accordingly .</description>
    <arm_group_label>Axon Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Control</intervention_name>
    <description>The sham procedure consists of a small needle puncture made in the groin to pass a standard femoral introducer sheath approximately 10 cm into the femoral vein, using standard access methods. The Axon Catheter and associated access accessories will not be inserted into the patient. The sham procedure duration will be similar to the treatment time for subject receiving the Axon therapy (~30 minutes).</description>
    <arm_group_label>Sham Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects ≥ 40 years of age&#xD;
&#xD;
          2. Chronic heart failure defined as at least one of the following:&#xD;
&#xD;
               1. Symptoms of HF requiring current treatment with diuretics for &gt; 30 days, AND&#xD;
&#xD;
               2. NYHA class II with a history of &gt; NYHA class II in the past year, NYHA class III,&#xD;
                  or ambulatory NYHA class IV symptoms (paroxysmal nocturnal dyspnea, orthopnea,&#xD;
                  dyspnea on mild or moderate exertion) at screening; or signs of HF (any rales&#xD;
                  post cough, chest x-ray demonstrating pulmonary congestion), AND&#xD;
&#xD;
               3. &gt; 1 HF hospital admission (with HF as the primary, or secondary diagnosis);&#xD;
&#xD;
                    -  OR - treatment with intravenous (IV) diuretics, or intensification of oral&#xD;
                       diuresis for HF in a healthcare facility within the 12 months prior to study&#xD;
                       entry;&#xD;
&#xD;
                    -  OR - NT-pro BNP value &gt; 150 pg/ml in normal sinus rhythm, &gt; 450 pg/ml in&#xD;
                       atrial fibrillation within the past 6 months;&#xD;
&#xD;
                    -  OR - BNP value &gt; 50 pg/ml in normal sinus rhythm, &gt; 150 pg/ml in atrial&#xD;
                       fibrillation within the past 6 months.&#xD;
&#xD;
          3. Ongoing stable GDMT HF management and management of potential comorbidities according&#xD;
             to the 2017 ACCF/AHA Guideline for the Management of Heart Failure, with no&#xD;
             significant changes [&gt;100% increase or 50% decrease] for a minimum of 1 month prior to&#xD;
             screening, that is expected to be maintained without change for at least 3 months.&#xD;
&#xD;
          4. LVEF &gt; 50 % (site determined by TTE) in the past 3 months.&#xD;
&#xD;
          5. Site determined elevated PCWP documented by right heart catheterization by PCWP ≥ 25&#xD;
             mmHg during supine ergometer exercise&#xD;
&#xD;
             a. PCWP to be evaluated by a Swan Ganz procedure performed either prior to the day of&#xD;
             the index procedure or on the day of the index procedure&#xD;
&#xD;
          6. Subject is willing and able to provide appropriate study-specific informed consent,&#xD;
             follow protocol procedures, and comply with follow-up visit requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. MI (type I) and/or percutaneous cardiac intervention within past 3 months; CABG in&#xD;
             past 3 months, or current indication for coronary revascularization.&#xD;
&#xD;
          2. Cardiac Resynchronization Therapy initiated within the past 3 months.&#xD;
&#xD;
          3. Advanced heart failure defined as one or more of the below:&#xD;
&#xD;
               1. ACC/AHA/ESC Stage D heart failure, non-ambulatory NYHA Class IV HF&#xD;
&#xD;
               2. Cardiac index &lt; 2.0 L/min/m2&#xD;
&#xD;
               3. Inotropic infusion (continuous or intermittent) for LV EF&lt; 30% within the past 6&#xD;
                  months&#xD;
&#xD;
               4. Subject is on the cardiac transplant waiting list&#xD;
&#xD;
          4. BMI &gt; 45 kg/m2&#xD;
&#xD;
          5. Inability to perform 6-minute walk test (distance &lt; 100 meters), OR ability to perform&#xD;
             6-minute walk test distance &gt; 450 meters.&#xD;
&#xD;
          6. Admission for HF within the 30 days prior to planned index procedure.&#xD;
&#xD;
          7. In the last 3 years no ejection fraction (EF) below 40&#xD;
&#xD;
          8. Systolic BP &lt; 100 mmHg or &gt; 170 mmHg despite appropriate medical management.&#xD;
&#xD;
          9. No evidence of orthostatic hypotension; defined as systolic blood pressure decrease of&#xD;
             &gt;20mmHg and/or increase in heart rate &gt;20 bpm upon going from supine to standing&#xD;
             position or requiring any treatment for orthostatic hypotension&#xD;
&#xD;
         10. Arterial oxygen saturation &lt; 90 % on room air.&#xD;
&#xD;
         11. Presence of significant valve disease defined by the site cardiologist as:&#xD;
&#xD;
               1. Mitral valve stenosis defined as &lt;1.5 cm2 (or greater than mild)&#xD;
&#xD;
               2. Mitral valve regurgitation defined as grade &gt; 3+ MR&#xD;
&#xD;
               3. Tricuspid valve regurgitation defined as grade &gt; 3+ TR&#xD;
&#xD;
               4. Aortic valve disease defined as &gt; 3+ AR or &gt; severe AS&#xD;
&#xD;
         12. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis,&#xD;
             cardiac amyloidosis, or other infiltrative cardiomyopathy (e.g., hemochromatosis,&#xD;
             sarcoidosis)&#xD;
&#xD;
         13. Vessel tortuosity or variant vascular anatomy that could preclude the access or&#xD;
             maneuvering of the interventional device from the access site to target vessel.&#xD;
&#xD;
         14. Mean resting right atrial pressure (RAP) &gt; 20 mmHg based upon screening right heart&#xD;
             catheterization.&#xD;
&#xD;
         15. History of severe liver cirrhosis&#xD;
&#xD;
         16. Dialysis dependent; or estimated-GFR &lt;25 ml/min/1.73 m2 by MDRD equation.&#xD;
&#xD;
         17. Baseline status of persistent atrial fibrillation with resting HR &gt;100 beats per&#xD;
             minute that could obfuscate RHC interpretation.&#xD;
&#xD;
         18. Chronic pulmonary disease requiring continuous home oxygen OR hospitalization for&#xD;
             exacerbation (including intubations) in the 12 months before study entry OR known&#xD;
             history of GOLD Class II or higher COPD.&#xD;
&#xD;
         19. Currently participating in conflicting investigational drug or device study.&#xD;
&#xD;
         20. Life expectancy &lt;12 months for non-cardiovascular reasons.&#xD;
&#xD;
         21. Any condition, or history of illness or surgery that, in the opinion of the&#xD;
             Investigator, might confound the results of the study or pose additional risks to the&#xD;
             patient.&#xD;
&#xD;
         22. Females who are not pregnant or lactating and not or planning to become pregnant for&#xD;
             the duration of the studyduring the next year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sierra Yearsley</last_name>
    <phone>16508670927</phone>
    <email>s.yearsley@axontherapies.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiology PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Farrell Mendelsohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Cardiovascular Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vijendra Swarup, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scripps Health</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rajeev Mohan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Price, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Liviu Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bluhm Cardiovascular Institute of Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ravi Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sean Pinney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Education and Research Cooperative</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Krishna Rocha-Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Fail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kavita Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Scott Hummel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Barry Borlaug, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Parag Goyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sumeet Mitter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Cardiac Care, Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nir Uriel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marat Fudim, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ralph Augostini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina, Gazes Cardiac Research Institute</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sheldon Litwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Keyur Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

